# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-19-019545
Filing Date
2019-04-12
Accepted
2019-04-12 17:00:30
Documents
5
Period of Report
2019-05-30
Effectiveness Date
2019-04-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | tv518711-def14a.htm | DEF 14A | 409246
2 | GRAPHIC | lg_protalix.jpg | GRAPHIC | 25457
3 | GRAPHIC | sig_yossi-maimon.jpg | GRAPHIC | 9221
4 | GRAPHIC | tv518711_pc1.jpg | GRAPHIC | 501173
5 | GRAPHIC | tv518711_pc2.jpg | GRAPHIC | 780075
| Complete submission text file | 0001144204-19-019545.txt |  | 2222867

Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 19746893
SIC: 2836 Biological Products, (No Diagnostic Substances)